Cargando…

Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial

BACKGROUND: A single low dose (0.25 mg/kg) of primaquine is recommended as a gametocytocide in combination with artemisinin-based combination therapies for Plasmodium falciparum but its effect on post-treatment gametocyte circulation and infectiousness to mosquitoes has not been quantified. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Bronner P., Tiono, Alfred B., Ouédraogo, Alphonse, Guelbéogo, Wamdaogo M., Bradley, John, Nebie, Issa, Siaka, Débé, Lanke, Kjerstin, Eziefula, Alice C., Diarra, Amidou, Pett, Helmi, Bougouma, Edith C., Sirima, Sodiomon B., Drakeley, Chris, Bousema, Teun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782330/
https://www.ncbi.nlm.nih.gov/pubmed/26952094
http://dx.doi.org/10.1186/s12916-016-0581-y
_version_ 1782419931357249536
author Gonçalves, Bronner P.
Tiono, Alfred B.
Ouédraogo, Alphonse
Guelbéogo, Wamdaogo M.
Bradley, John
Nebie, Issa
Siaka, Débé
Lanke, Kjerstin
Eziefula, Alice C.
Diarra, Amidou
Pett, Helmi
Bougouma, Edith C.
Sirima, Sodiomon B.
Drakeley, Chris
Bousema, Teun
author_facet Gonçalves, Bronner P.
Tiono, Alfred B.
Ouédraogo, Alphonse
Guelbéogo, Wamdaogo M.
Bradley, John
Nebie, Issa
Siaka, Débé
Lanke, Kjerstin
Eziefula, Alice C.
Diarra, Amidou
Pett, Helmi
Bougouma, Edith C.
Sirima, Sodiomon B.
Drakeley, Chris
Bousema, Teun
author_sort Gonçalves, Bronner P.
collection PubMed
description BACKGROUND: A single low dose (0.25 mg/kg) of primaquine is recommended as a gametocytocide in combination with artemisinin-based combination therapies for Plasmodium falciparum but its effect on post-treatment gametocyte circulation and infectiousness to mosquitoes has not been quantified. METHODS: In this randomised, double-blind, placebo-controlled trial, 360 asymptomatic parasitaemic children aged 2-15 years were enrolled and assigned to receive: artemether-lumefantrine (AL) and a dose of placebo; AL and a 0.25 mg/kg primaquine dose; or AL and a 0.40 mg/kg primaquine dose. On days 0, 2, 3, 7, 10 and 14, gametocytes were detected and quantified by microscopy, Pfs25 mRNA quantitative nucleic acid sequence based amplification (QT-NASBA), and quantitative reverse-transcriptase PCR (qRT-PCR). For a subset of participants, pre- and post-treatment infectiousness was assessed by mosquito feeding assays on days -1, 3, 7, 10 and 14. RESULTS: Both primaquine arms had lower gametocyte prevalences after day 3 compared to the placebo arm, regardless of gametocyte detection method. The mean (95 % confidence interval) number of days to gametocyte clearance in children with patent gametocytes on day 0 (N = 150) was 19.7 (14.6 – 24.8), 7.7 (6.3 – 9.1) and 8.2 (6.7 – 9.6) for the AL-placebo, the 0.25 mg/kg primaquine dose and the 0.40 mg/kg primaquine dose arms, respectively. While 38.0 % (30/79) of selected gametocytaemic individuals were infectious before treatment, only 1/251 participant, from the AL-placebo group, infected mosquitoes after treatment. CONCLUSIONS: We observed similar gametocyte clearance rates after 0.25 and 0.40 mg/kg primaquine doses. Infectivity to mosquitoes after AL was very low and absent in primaquine arms. CLINICALTRIALS.GOV REGISTRATION: NCT01935882 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0581-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4782330
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47823302016-03-09 Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial Gonçalves, Bronner P. Tiono, Alfred B. Ouédraogo, Alphonse Guelbéogo, Wamdaogo M. Bradley, John Nebie, Issa Siaka, Débé Lanke, Kjerstin Eziefula, Alice C. Diarra, Amidou Pett, Helmi Bougouma, Edith C. Sirima, Sodiomon B. Drakeley, Chris Bousema, Teun BMC Med Research Article BACKGROUND: A single low dose (0.25 mg/kg) of primaquine is recommended as a gametocytocide in combination with artemisinin-based combination therapies for Plasmodium falciparum but its effect on post-treatment gametocyte circulation and infectiousness to mosquitoes has not been quantified. METHODS: In this randomised, double-blind, placebo-controlled trial, 360 asymptomatic parasitaemic children aged 2-15 years were enrolled and assigned to receive: artemether-lumefantrine (AL) and a dose of placebo; AL and a 0.25 mg/kg primaquine dose; or AL and a 0.40 mg/kg primaquine dose. On days 0, 2, 3, 7, 10 and 14, gametocytes were detected and quantified by microscopy, Pfs25 mRNA quantitative nucleic acid sequence based amplification (QT-NASBA), and quantitative reverse-transcriptase PCR (qRT-PCR). For a subset of participants, pre- and post-treatment infectiousness was assessed by mosquito feeding assays on days -1, 3, 7, 10 and 14. RESULTS: Both primaquine arms had lower gametocyte prevalences after day 3 compared to the placebo arm, regardless of gametocyte detection method. The mean (95 % confidence interval) number of days to gametocyte clearance in children with patent gametocytes on day 0 (N = 150) was 19.7 (14.6 – 24.8), 7.7 (6.3 – 9.1) and 8.2 (6.7 – 9.6) for the AL-placebo, the 0.25 mg/kg primaquine dose and the 0.40 mg/kg primaquine dose arms, respectively. While 38.0 % (30/79) of selected gametocytaemic individuals were infectious before treatment, only 1/251 participant, from the AL-placebo group, infected mosquitoes after treatment. CONCLUSIONS: We observed similar gametocyte clearance rates after 0.25 and 0.40 mg/kg primaquine doses. Infectivity to mosquitoes after AL was very low and absent in primaquine arms. CLINICALTRIALS.GOV REGISTRATION: NCT01935882 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-016-0581-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-03-08 /pmc/articles/PMC4782330/ /pubmed/26952094 http://dx.doi.org/10.1186/s12916-016-0581-y Text en © Gonçalves et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gonçalves, Bronner P.
Tiono, Alfred B.
Ouédraogo, Alphonse
Guelbéogo, Wamdaogo M.
Bradley, John
Nebie, Issa
Siaka, Débé
Lanke, Kjerstin
Eziefula, Alice C.
Diarra, Amidou
Pett, Helmi
Bougouma, Edith C.
Sirima, Sodiomon B.
Drakeley, Chris
Bousema, Teun
Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
title Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
title_full Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
title_fullStr Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
title_full_unstemmed Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
title_short Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
title_sort single low dose primaquine to reduce gametocyte carriage and plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782330/
https://www.ncbi.nlm.nih.gov/pubmed/26952094
http://dx.doi.org/10.1186/s12916-016-0581-y
work_keys_str_mv AT goncalvesbronnerp singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT tionoalfredb singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT ouedraogoalphonse singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT guelbeogowamdaogom singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT bradleyjohn singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT nebieissa singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT siakadebe singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT lankekjerstin singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT eziefulaalicec singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT diarraamidou singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT petthelmi singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT bougoumaedithc singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT sirimasodiomonb singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT drakeleychris singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial
AT bousemateun singlelowdoseprimaquinetoreducegametocytecarriageandplasmodiumfalciparumtransmissionafterartemetherlumefantrineinchildrenwithasymptomaticinfectionarandomiseddoubleblindplacebocontrolledtrial